Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-02-12 @ 7:34 PM
Study NCT ID:
NCT01851551
Status:
COMPLETED
Last Update Posted:
2020-01-03
First Post:
2013-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Sponsor:
Acrotech Biopharma Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CA00005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None